Tag - VRCA

Developments

Verrica Pharma gets complete response letter for molluscum contagiosum drug

The FDA issued Verrica Pharmaceuticals (NASDAQ:VRCA) a complete response letter (CRL) regarding the company’s NDA for VP-102. VP-102 is a topical cantharidin solution designed to treat molluscum contagiosum, a viral...

July 14, 2020

Developments

FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

The FDA accepted Verrica Pharmaceuticals’ (NASDAQ:VRCA) NDA for its molluscum contagiosum drug candidate, VP-102, assigning a PDUFA date of July 13, 2020. VP-102 is a topical cantharidin solution designed to treat...

November 27, 2019

Developments

Verrica Pharma submits NDA for molluscum contagiosum drug

Verrica Pharmaceuticals (NASDAQ:VRCA) submitted an NDA to the FDA for its molluscum contagiosum drug candidate, VP-102. Molluscum contagiosum is a viral skin infection that currently has no FDA-approved therapies. VP...

September 16, 2019

Tag - VRCA

Verrica Pharma gets complete response letter for molluscum contagiosum drug

FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

Verrica Pharma submits NDA for molluscum contagiosum drug

General

More